Bellicum brings in some CAR-T assets; Sangamo heralds Phase II success with HIV therapy;

@FierceBiotech: AstraZeneca bets on the future of the 'secretome,' joining a $100M research effort. Story | Follow @FierceBiotech

@JohnCFierce: If @woodfordfunds didn't know about the questions circulating around $NWBO, you have to wonder if the DC vax thing came up for review. | Follow @JohnCFierce

@DamianFierce: A lot of culturally embarrassing quotes in this, but reporters calling 5% "an obscure black movement" is as damning as anything Shkreli says. | Follow @DamianFierce

> Bellicum Pharmaceuticals ($BLCM) signed a deal with Astellas for the rights to cancer-fighting cell therapies that dovetail with its work in CAR-T treatments. More

> Sanofi ($SNY) is reportedly close to hiring a Morgan Stanley banker to sit at the head of its M&A operation. News

> Sangamo Biosciences ($SGMO) said its HIV therapy succeeded in a pair of Phase II trials. Release

Medical Device News

@FierceMedDev: Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. More | Follow @FierceMedDev

@EmilyWFierce: Novian Health reveals positive study results for breast cancer laser ablation device. Article | Follow @EmilyWFierce

> Medtronic, Samsung partner to develop neuromodulation implant apps for smart devices. Story

> Lab experts lash out at FDA move to beef up regulation of lab-developed tests. News

Pharma News

@FiercePharma: NICE backs Astellas' Xtandi in pre-chemo patients, but J&J's Zytiga isn't so lucky. More | Follow @FiercePharma

@EricPFierce: #Sun #Pharma to launch generic Gleevec Feb. 1 but has said it won't be #manufacturing it at troubled Halol plant. Story | Follow @EricPFierce

@CarlyHFierce: Horizon shells out $510 million for access to gout med Kyrstexxa. News | Follow @CarlyHFierce

> Discount sways U.K. cost gatekeeper on AstraZeneca's ovarian cancer med Lynparza. More

> Sanofi's and Regeneron's Praluent wins top billing on UnitedHealth Group's formulary. Article

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.